Policy· August 31, 2026 · 18 min read
Topic
HCPCS Coding
Healthcare Common Procedure Coding System codes, biosimilar Q-codes, J-codes, buy-and-bill billing, and reimbursement.
Specialty· August 30, 2026 · 23 min read
Libre Duo's Dual Glucose-Ketone De Novo Is Not a Medicare CGM Coverage Decision
Approvals· August 27, 2026 · 20 min read
Imaavy's wAIHA Approval Is a Steroid-Gated, q4w Indication: J9256 Does Not Auto-Cover It
Pricing & Access· July 31, 2026 · 22 min read
Radioligand Therapy Access Landscape: Pluvicto, Lutathera & ITM PDUFA
By Ran Chen#Market Access#FDA Approval#HCPCS Coding
Pricing & Access· July 14, 2026 · 18 min read
Generalized Myasthenia Gravis (gMG) Access and Dosing Landscape
By Ran Chen#Rare Disease#Payer Policy#HCPCS Coding
Pricing & Access· July 14, 2026 · 20 min read
PNH Access Landscape: C5 Blockers, Orals, and the Biosimilar Cliff
By Ran Chen#Rare Disease#Payer Policy#HCPCS Coding
Pricing & Access· July 13, 2026 · 17 min read
Duchenne Muscular Dystrophy Access Landscape: Elevidys, Oligonucleotides, and Duvyzat
By Ran Chen#Rare Disease#Gene Therapy#HCPCS Coding
Pricing & Access· July 5, 2026 · 17 min read
Winrevair (sotatercept) access landscape: PAH cost and coverage after ZENITH
Pricing & Access· June 24, 2026 · 26 min read
Roche Genentech Portfolio Dossier: Subcutaneous Biologic Transitions
By Ran Chen#Purple Book#Biosimilars#J-Code
Generics· June 22, 2026 · 19 min read
Generic Lanreotide Acetate: 505(b)(2) Approvals and Medical-Benefit Coding
By Ran Chen#Generics#FDA Approval#Orange Book